Frontlight ResearchEarly access
Not yet recruitingPhase 3
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
Key facts
- Who runs it
- Centre Hospital Region Metz Thionville
- Where
- France51 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 544 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 1 Jan 2030
- Type of study
- Interventional
- Record updated
- 9 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age ≥ 18 years
- Admission to ICU or intermediate care for less than 2 days
- Admission to hospital for less than 5 days
- Diagnosis of influenza pneumonia with • PCR positive for Influenza dated less than 5 days • AND focal shadowing/infiltrates on chest X-ray or CT-scan • AND at least one of the following: cough, purulent sputum, chest pain or dyspnoea
- Requirement of supplemental oxygen at a flow rate of at least 3 L/min OR non-invasive ventilation OR high flow oxygen therapy OR invasive mechanical ventilation
- Written informed or emergency consent
- Ongoing medical insurance
Who cannot take part
- Subject with shock on enrolment and on ongoing vasopressor therapy (≥ 0.25 microg/kg/min)
- Indication for corticosteroid therapy in a dosage above 0.5 mg/kg/day prednisone-equivalent
- Bone marrow transplant or chemotherapy-induced neutropenia
- Known allergy to dexamethasone or to one of its excipients
- Co-infection with COVID-19
- Known active tuberculosis or fungal infection
- Active viral hepatitis or active herpes virus infection
- Moribund state
- Patient at risk of strongyloidiasis
- Subject deprived of liberty or under a legal protective measure (example: patients under guardianship or curatorship)
- Pregnant or breastfeeding woman
- Lack of clinical equipoise by the attending physician and/or the presence of a substantial risk associated with the patients’ participation in the trial
- Uncontrolled psychotic states
- Pheochromocytoma
- Cardiogenic shock secondary to influenza myocarditis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the efficacy of dexamethasone versus placebo in patients with severe influenza on a hierarchical composite endpoint of all-cause mortality, number of ventilator-free days and number of ICU-free days between day 0 and day 28.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
- Record updated
- 9 October 2026